To evaluate the timing of transcriptional expression changes of GATA1, NFE2, and PF4 in relation to the onset of thrombocytopenia during treatment with BMS-986158, Table 2 summarizes the results from a phase 1/2a clinical study (NCT02419417). Here, NFE2 is linked to Thrombocytopenia.